title: Pharmacologic treatment options for non-insulin-dependent diabetes mellitus.
abstract: Non-insulin-dependent diabetes mellitus (NIDDM) is a major health concern for clinicians who are responsible for the care of an aging population. The relationship between hyperglycemia and the chronic complications of retinopathy, nephropathy, and neuropathy has been established in patients with insulin-dependent diabetes mellitus, and it is extremely likely that such a relationship exists in patients with NIDDM as well. Diet and exercise are the cornerstone for the management of NIDDM. The assessment of glycemic control should determine which patients with NIDDM need more aggressive intervention to control hyperglycemia. Pharmacologic treatment options include oral administration of the sulfonylureas, a biguanide, and an alpha-glucosidase inhibitor and subcutaneous administration of insulin. Extensive education about diabetes and self-monitoring of blood glucose levels are important components in maximizing glycemic control. Additional pharmacologic treatment options are necessary when adequate individualized treatment goals are not attained. The goal of therapy is to prevent the onset or progression of long-term microvascular and macrovascular complications. In this review, we present the therapeutic options and outline our approach to the pharmacologic treatment of NIDDM. Relevant medical literature on each treatment modality is reviewed, and the cost of therapy with use of each medication is provided.
authors.affiliation: Division of Endocrinology/Metabolism, Mayo Clinic Rochester, MN 55905, USA.
authors.forename: G H
authors.initials: GH
authors.lastname: Tan
authors.forename: R L
authors.initials: RL
authors.lastname: Nelson
mesh_terms: D020909:Acarbose; D015190:Blood Glucose Self-Monitoring; D003365:Costs and Cost Analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D004791:Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D005959:Glucosidases / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use*; D007328:Insulin / Q000191:economics / Q000627:therapeutic use; D008687:Metformin / Q000191:economics / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000191:economics / Q000627:therapeutic use; D014312:Trisaccharides / Q000191:economics / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D014312:Trisaccharides; D008687:Metformin; D005959:Glucosidases; D020909:Acarbose